Glaucoma is a leading cause of irreversible blindness worldwide and often goes undiagnosed until vision loss is advanced. Population-wide screening has long been considered impractical, but recent ...
In late 2025, a group of researchers that included Maria Emfietzoglou, MD, and Victor S.M.C. Correa, MD, published a paper titled, “Inner Plexiform Layer Substrata Are Discernible with Commercial OCT ...
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 Earnings Call Transcript March 4, 2026 Sight Sciences, Inc. beats earnings expectations. Reported EPS is $-0.07841, expectations were $-0.15. Operator: Good ...
Glaucoma performance stabilized after lapping 2025 regulatory headwinds that restricted multiple MIGS procedures in ...
Sight Sciences (NASDAQ:SGHT) reported fourth-quarter 2025 results highlighting growth in both its interventional glaucoma and ...
MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, ...
Sight Sciences (Nasdaq:SGHT) today announced new clinical data supporting its Omni minimally invasive glaucoma surgery (MIGS) device. Menlo Park, California–based Sight Sciences conducted a systematic ...
Sight Sciences Inc. (NASDAQ:SGHT) on Tuesday announced that UnitedHealthcare has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results